230 related articles for article (PubMed ID: 4016793)
41. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes.
Vergne P; Liagre B; Bertin P; Cook-Moreau J; Treves R; Beneytout JL; Rigaud M
J Rheumatol; 1998 Mar; 25(3):433-40. PubMed ID: 9517759
[TBL] [Abstract][Full Text] [Related]
42. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
43. Allelic variation in the dihydrofolate reductase gene at amino acid position 95 contributes to antifolate resistance in Chinese hamster cells.
Yu M; Melera PW
Cancer Res; 1993 Dec; 53(24):6031-5. PubMed ID: 8261418
[TBL] [Abstract][Full Text] [Related]
44. Distribution and degradation of [3H]methotrexate after intravenous and cerebral intraventricular injection in primates.
Kimelberg HK; Biddlecome SM; Bourke RS
Cancer Res; 1977 Jan; 37(1):157-65. PubMed ID: 401470
[TBL] [Abstract][Full Text] [Related]
45. Effect of methotrexate on dihydrofolate reductase activity in methotrexate-resistant human KB cells.
Domin BA; Grill SP; Bastow KF; Cheng YC
Mol Pharmacol; 1982 Mar; 21(2):478-82. PubMed ID: 7099148
[TBL] [Abstract][Full Text] [Related]
46. Determination of methotrexate in human serum by high-performance liquid chromatography combined with pseudo template molecularly imprinted polymer.
Liu X; Liu J; Huang Y; Zhao R; Liu G; Chen Y
J Chromatogr A; 2009 Oct; 1216(44):7533-8. PubMed ID: 19559443
[TBL] [Abstract][Full Text] [Related]
47. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis.
Ravelli A; Di Fuccia G; Molinaro M; Ramenghi B; Zonta L; Regazzi MB; Martini A
J Rheumatol; 1993 Sep; 20(9):1573-7. PubMed ID: 8164218
[TBL] [Abstract][Full Text] [Related]
48. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
49. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant.
Wong LS; Tymms KE; Buckley NA
Intern Med J; 2009 Jun; 39(6):379-83. PubMed ID: 19580617
[TBL] [Abstract][Full Text] [Related]
50. Action of intermediate doses of methotrexate on dihydrofolate reductase in malignant diseases.
Tzortzatou-Stathopoulou F; Zavitsa-Pateli H; Mousatos G; Prodromou N; Kairis M; Pappas J
Pediatr Hematol Oncol; 1987; 4(1):43-53. PubMed ID: 3152912
[TBL] [Abstract][Full Text] [Related]
51. [Tissue concentration of methotrexate in osteosarcoma after high-dose infusion].
Amino K
Nihon Seikeigeka Gakkai Zasshi; 1982 Aug; 56(8):765-76. PubMed ID: 6984057
[TBL] [Abstract][Full Text] [Related]
52. [Serum methotrexate determination by microbiological assay in patients receiving high-dosage methotrexate (author's transl)].
Krisch K; Kotz D; Mehta BM
Wien Klin Wochenschr; 1977 Jul; 89(14):479-81. PubMed ID: 268729
[TBL] [Abstract][Full Text] [Related]
53. Methotrexate measurements in plasma: comparison of enzyme multiplied immunoassay technique, TDx fluorescence polarization immunoassay, and high pressure liquid chromatography.
Slørdal L; Prytz PS; Pettersen I; Aarbakke J
Ther Drug Monit; 1986; 8(3):368-72. PubMed ID: 3529519
[TBL] [Abstract][Full Text] [Related]
54. [Clinical significance of non-renal elimination mechanisms of methotrexate (MTX)].
Erttmann R; Gkanatsas A
Monatsschr Kinderheilkd; 1985 Aug; 133(8):516-9. PubMed ID: 3876505
[TBL] [Abstract][Full Text] [Related]
55. [New aspects of the determination of blood methotrexate levels in leukemic children].
Schuler D; Borsi J; Koós R; Révész T; Kardos G; Somló P
Monatsschr Kinderheilkd; 1986 Oct; 134(10):765-8. PubMed ID: 3467178
[TBL] [Abstract][Full Text] [Related]
56. A fluorescence study of substrate and inhibitor binding to bovine liver dihydrofolate reductase.
Degan P; Carpano P; Cercignani G; Montagnoli G
Int J Biochem; 1989; 21(3):291-5. PubMed ID: 2744204
[TBL] [Abstract][Full Text] [Related]
57. [Bolus and maintenance infusion of high-dose methotrexate].
Amino K; Kawaguchi N; Matsumoto S; Manabe J; Tabata D; Machida M
Gan To Kagaku Ryoho; 1989 May; 16(5):2045-9. PubMed ID: 2730094
[TBL] [Abstract][Full Text] [Related]
58. Aspects of the reversal of methotrexate toxicity in rodents.
Kisliuk RL; Tattersall MH; Gaumont Y; Pastore EJ; Brown B
Cancer Treat Rep; 1977 Jul; 61(4):647-50. PubMed ID: 301779
[TBL] [Abstract][Full Text] [Related]
59. 7-Hydroxy-methotrexate and clinical toxicity following high-dose methotrexate therapy.
Erttmann R; Bielack S; Landbeck G
J Cancer Res Clin Oncol; 1985; 109(1):86-8. PubMed ID: 3855853
[TBL] [Abstract][Full Text] [Related]
60. Dose-dependent metabolism of methotrexate in man and rhesus monkeys.
Jacobs SA; Stoller RG; Chabner BA; Johns DG
Cancer Treat Rep; 1977 Jul; 61(4):651-6. PubMed ID: 406997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
